nanotech investing Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
nanotech investing Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR
nanotech investing Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
nanotech investing Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
nanotech investing Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT XR in the Journal of Clinical Endocrinology and Metabolism
nanotech investing Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
nanotech investing Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
nanotech investing Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR
nanotech investing Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
nanotech investing Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
